Alizapride
Alizapride is a dopamine antagonist with antiemetic and prokinetic properties used for the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.
Pharmacology[edit]
Alizapride works by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, which helps to reduce the feeling of nausea and prevents vomiting. It also increases the movements or contractions of the stomach and intestines, aiding in the digestion process.
Medical uses[edit]
Alizapride is primarily used to prevent and treat nausea and vomiting, including postoperative nausea and vomiting. It can also be used to treat nausea and vomiting caused by radiation therapy, cytotoxic chemotherapy, and general anesthesia. In some cases, it may be used to treat gastrointestinal disorders such as gastroparesis and gastroenteritis.
Side effects[edit]
Like other dopamine antagonists, alizapride can cause a range of side effects. The most common side effects include drowsiness, restlessness, and diarrhea. Less common side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and hypotension.
History[edit]
Alizapride was first synthesized in the 1970s by the French pharmaceutical company Sanofi. It is currently marketed in several countries, including France, Italy, and Spain, but is not approved for use in the United States or the United Kingdom.
See also[edit]
Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology
| Major chemical drug groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Antiemetics (A04) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Prokinetic agents | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This prokinetic agents related article is a stub.
|
